If You Invested $1000 in Thermo Fisher Scientific 10 Years Ago, This Is How Much You'd Have Now

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.What if you'd invested in Thermo Fisher Scientific (TMO) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?Thermo Fisher Scientific's Business In-DepthWith that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation.In terms of end market served, there are four divisions-- pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics.Following the acquisition, the new reporting segments are:The Life Sciences Solutions segment, representing 22.5% of total revenues in 2024, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2024, this business registered a decline of 3.5% from the 2023 level.In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.The Analytical Instruments (formerly known as Analytical Technology) segment, which represented 17.4% of total revenues in 2024, has been renamed to reflect the transfer of the bioprocess production business to the newly formed Life Sciences Solutions Segment. In 2024, this business registered growth of 2.7% from the 2023 level.The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2024, this business registered growth of 2.4% from the 2023 level.Laboratory Products and Biopharma Services, formerly known as Laboratory Products and Services, represents 54% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2024, this business registered growth of 0.5% from the 2023 level. Bottom LineWhile anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Thermo Fisher Scientific ten years ago, you're probably feeling pretty good about your investment today.According to our calculations, a $1000 investment made in November 2015 would be worth $4,383.96, or a gain of 338.40%, as of November 14, 2025, and this return excludes dividends but includes price increases.Compare this to the S&P 500's rally of 233.04% and gold's return of 268.68% over the same time frame.Analysts are anticipating more upside for TMO.Thermo Fisher continues to strengthen its foundation by consistently progressing its growth strategy. The company's latest round of innovations supports scientific breakthroughs, advances precision medicine and greater lab productivity for customers. Thermo Fisher is embedding OpenAI's capabilities into its products and services to make an even bigger impact for customers and enhance productivity. Strategic acquisitions, such as the newly added Solventum's Purification and Filtration Business, further enhance its offerings. Our model forecasts a 5.1% CAGR growth in the company's revenues through 2025-2027. Meanwhile, a highly leveraged balance sheet poses liquidity concerns. Shifting U.S. policies have weighed on the academic and government end-market clients, affecting its sales. Currency woes add to the worry.The stock is up 8.08% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 12 higher, for fiscal 2025. The consensus estimate has moved up as well.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks